Medicare Enrolled
Dr. Shayma Kazmi, MD
Hematology & Oncology · Philadelphia, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kazmi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kazmi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kazmi
Dr. Shayma Kazmi is a hematology & oncology specialist in Philadelphia, PA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Kazmi performed 11,459 Medicare services across 1,204 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kazmi received a total of $669,352 from 34 pharmaceutical and/or device companies across 741 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kazmi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 18% volume in PA
$669,352 industry payments
Medicare Practice Summary
Medicare Utilization ↗11,459
Medicare services
Top 18% in PA for hematology & oncology
1,204
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~603 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
5,100 | $0 | $1 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
3,900 | $0 | $5 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
585 | $146 | $406 |
| Anti-nausea injection (ondansetron/Zofran) | 224 | $0 | $10 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
217 | $67 | $200 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
183 | $8 | $60 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
157 | $8 | $32 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
134 | $117 | $550 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
99 | $12 | $72 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
99 | $146 | $549 |
| New patient office visit, complex (60-74 min) | 87 | $184 | $574 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
81 | $100 | $289 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
78 | $107 | $306 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
62 | $2 | $45 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
60 | $11 | $60 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
42 | $25 | $110 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
42 | $14 | $75 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
42 | $1 | $3 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
41 | $139 | $476 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
36 | $57 | $185 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
34 | $57 | $275 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
31 | $49 | $235 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
26 | $4 | $14 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
26 | $6 | $27 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
23 | $18 | $60 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
21 | $1 | $22 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
15 | $110 | $378 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
14 | $33 | $145 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.1% high complexity
82.5% medium
14.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$669,352
Total received (2018-2024)
Avg $95,622/year across 7 years
Top 1% in PA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
34
Companies
741
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$500,792 (74.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$162,775 (24.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,784 (0.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$32,069
2023
$51,293
2022
$42,935
2021
$114,251
2020
$117,953
2019
$230,782
2018
$80,068
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
JAZZ PHARMACEUTICALS INC.
$22,246
Amgen Inc.
$5,874
Takeda Pharmaceuticals U.S.A., Inc.
$1,978
AstraZeneca Pharmaceuticals LP
$1,478
Novocure Inc.
$302
Daiichi Sankyo Inc.
$113
Merck Sharp & Dohme LLC
$47
E.R. Squibb & Sons, L.L.C.
$18
Celgene Corporation
$15
Top 3 companies account for 93.8% of 2024 payments
All-time payments by company (2018-2024) ›
Lilly USA, LLC
$147,517
Takeda Pharmaceuticals U.S.A., Inc.
$143,350
Foundation Medicine, Inc.
$81,845
Merck Sharp & Dohme Corporation
$80,759
JAZZ PHARMACEUTICALS INC.
$60,639
Jazz Pharmaceuticals Inc.
$41,808
Eisai Inc.
$36,706
EISAI INC.
$32,795
AstraZeneca Pharmaceuticals LP
$9,358
Gilead Sciences, Inc.
$8,046
Amgen Inc.
$5,874
Eli Lilly and Company
$5,260
PFIZER INC.
$3,488
Immunomedics, Inc.
$2,812
Bayer HealthCare Pharmaceuticals Inc.
$2,574
Eli Lilly Export S.A. Puerto Rico Branch
$1,725
Regeneron Healthcare Solutions, Inc.
$1,592
E.R. Squibb & Sons, L.L.C.
$1,447
EMD Serono, Inc.
$520
Novocure Inc.
$367
Novartis Pharmaceuticals Corporation
$245
Bayer Healthcare Pharmaceuticals Inc.
$125
Daiichi Sankyo Inc.
$113
Genentech USA, Inc.
$68
TESARO, Inc.
$65
Merck Sharp & Dohme LLC
$47
ALCRESTA THERAPEUTICS, INC.
$42
Celgene Corporation
$34
Clovis Oncology, Inc.
$30
AbbVie, Inc.
$23
Astellas Pharma US Inc
$22
Boehringer Ingelheim Pharmaceuticals, Inc.
$21
Incyte Corporation
$19
Shire North American Group Inc
$15
Top 3 companies account for 55.7% of all-time payments
Associated products mentioned in payments ›
ALUNBRIG · Alecensa · Avastin · BEVESPI AEROSPHERE · Bavencio · CYRAMZA · DIFICID · EMPLICITI · EXKIVITY · Enhertu · FASLODEX · FOUNDATIONONE · FOUNDATIONONE CDX · FOUNDATIONONE LIQUID · Halaven · IBRANCE · IMFINZI · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LORBRENA · Lenvima · MEKINIST · MYLOTARG · NINLARO · Nubeqa · ONTRUZANT · OPDIVO · Oncology · Optune · Perjeta · Pomalyst · RELIZORB · Rubraca · SANDOSTATIN · STIOLTO RESPIMAT · SUTENT · Stivarga · TAGRISSO · TALZENNA · TECENTRIQ · Tepmetko · Trodelvy · VELCADE · VERZENIO · VYXEOS · Venclexta · Vitrakvi · XALKORI · XTANDI · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (75%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for hematology & oncology in PA.
Geographic Context
Hematology & oncology specialists within 10 mi
278
Per 100K population
17.6
County median income
$60,698
Nearest hospital
FRIENDS HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kazmi is a mixed practice specialist, with above-average Medicare volume (top 18% in PA), with speaking/promotional industry engagement in the top 1% of PA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kazmi experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Kazmi performed 5,100 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kazmi receive payments from pharmaceutical companies?
Yes. Dr. Kazmi received a total of $669,352 from 34 companies across 741 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kazmi's costs compare to other hematology & oncology specialists in Philadelphia?
Dr. Kazmi's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kazmi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Philadelphia
Browse hematology & oncology specialists in Philadelphia ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in PA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in PA
Which PA hematology & oncology specialists receive the most from drug and device companies.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
By company
Foundation Medicine, Inc. Payments to Doctors
See all physicians who received payments from Foundation Medicine, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology